ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Q&As

Q&As

©Designua/Shutterstock.com

Treatment with rituximab and infliximab reduce the expression of Carboxypeptidase B, the complement peptide C5a and osteopontin in the synovial fluid of rheumatoid arthritis patients.

Daniel Clauw, M.D.

All pain is not created equal and treating it as if it is all the same may lead doctors down the wrong path, says the University of Michigan's Daniel Clauw, M.D.

Kenneth Saag, M.D.

In this Q&A, Dr. Saag discusses the status of prednisone to treat rheumatoid arthritis, new treatments for osteoporosis and more.

(©Wollertz/Shutterstock.com)

University of Michigan rheumatologist Daniel Clauw, M.D., speaks with Rheumatology Network about treating pain with cannabinoids. In rheumatology, studies are ongoing.

Daniel Clauw, M.D.

For rheumatology patients, opioids have more immediate risks than addiction, says the University of Michigan's Daniel Clauw, M.D., in an interview with Rheumatology Network.

Leonard Calabrese, D.O.

With the spread of Zika virus rating as a "public health emergency" by the World Health Organization, another emerging mosquito-borne illness is worrying rheumatologists: chikungunya.

Eric Morand, M.D., PhD.

Eric Morand, M.D., Ph.D., Director of Rheumatology at Monash Health in Australia, speaks with Rheumatology Network about his recent article in Nature Reviews Rheumatology.

Pages

Subscribe to Q&As on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.